Regeneron Pharmaceuticals, Inc. (0R2M)
LSE
736.49
-8.21 (-1.10%)
Closed
Oct 8, 2026
Day's Range
723.55755.79
52 wk Range
541.00870.00
Financial Statements - 0R2M - Regeneron Pharmaceuticals, Inc.
Revenue
115.52M▲ 375.7%
Net Income
-30.60M▲ 71.9%Net Margin -26.5%
EBITDA
-28.81M▲ 71.0%
Free Cash Flow
-16.65M▲ 82.0%
Income Statement
| Period Ending | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|
| Sales | 115.52M | 24.28M | 22.23M | 10.88M |
| Cost of Goods | - | - | - | - |
| Gross Profit | - | - | - | - |
 Operating Expense | - | - | - | - |
| Operating Income | -39.40M | -109.82M | -87.20M | -47.91M |
| Non-Operating Interest | - | - | - | - |
| Other Income Expense | 8.72M | - | -9.75M | - |
| Pre Tax Income | -30.60M | -109M | -92.87M | -46.03M |
| Income Tax | - | - | - | - |
| Net Income | -30.60M | -109M | -92.87M | -46.03M |
| EPS Basic | -0.52 | -2.09 | -2.21 | -1.37 |
| EPS Diluted | -0.52 | -2.09 | -2.21 | -1.37 |
| Basic Shares Outstanding | 58.68M | 52.03M | 41.99M | 33.65M |
| Diluted Shares Outstanding | 58.68M | 52.03M | 41.99M | 33.65M |
| Ebit | - | - | - | - |
| Ebitda | -28.81M | -99.19M | -87.37M | -45.55M |
| Net Income Continuous Operations | -30.60M | -109M | -92.87M | -46.03M |
| Minority Interests | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
